GLP-1 and Mood: What the Regulator Reviews Found

What the review concluded

The European Medicines Agency began a review in July 2023 after case reports involving liraglutide and semaglutide. In April 2024 its safety committee concluded that the available evidence does not support a causal association between GLP-1 receptor agonists and suicidal and self-injurious thoughts and actions, and that no update to the product information was warranted.

That conclusion rested on non-clinical studies, trial data, post-marketing surveillance and a study of electronic health records, which did not support a causal association either. It is a substantial answer to a specific question.

Being precise about what it settles matters, in both directions:

It does not mean nobody experienced what they reported. A finding of no causal association at population level is not a statement about any individual, and it is not a reason to dismiss what someone tells you or what you notice in yourself.
It does mean the population-level signal was examined properly and was not confirmed. That is a meaningful result and not a shrug. Reviews of this kind do sometimes end with a label change, and this one did not.

The mood changes people describe

Set aside the safety signal and there is a separate, quieter set of experiences that come up constantly and get almost no attention, largely because they are difficult to attribute to anything.

A flatness alongside the quiet

The food noise going silent is the effect people most want. Some describe a broader dulling arriving with it, where things other than food are less compelling too. It is not universal, and it is worth mentioning to a prescriber when it happens.

Losing a coping mechanism

For anyone who has eaten in response to stress for years, that route closing is a real loss even when the outcome is wanted. Nothing has replaced it, and the underlying stress did not go anywhere.

Feeling unwell for weeks

Persistent nausea and fatigue drag mood down on their own. Attributing the low mood to the drug and attributing it to feeling ill for a month are not easy to separate, and after a dose increase both are plausible.

Identity and other people

Substantial weight loss changes how people treat you, and not always comfortably. This is well described after bariatric surgery and it applies here for the same reasons.

None of this is a warning against treatment. It is the part of the experience that gets left out of a summary that only covers nausea and results, and hearing that other people report it is worth something on its own.

What makes attribution hard

Almost everything about the situation confounds the question. The months in which mood might change are also the months of a large physiological change, deliberate calorie restriction, altered sleep and altered social life. Low mood in that period has several plausible explanations and no obvious way to distinguish between them from the inside.

Two things help, and neither is complicated:

Dates. Whether a change began within days of a dose increase or drifted in over two months is the single most informative thing about it, and it is precisely what memory reconstructs badly.
Some record other than recall. A rough note of how a week went, made during that week, is worth more than an honest attempt three months later to remember when things shifted.

This is the same reason the side effects timeline is organised by date. A symptom that clusters around dose increases and a symptom that arrived once and stayed are different findings, and only a record tells them apart.

When to seek help

Regardless of cause, and without waiting to work out whether the medication is involved:

Thoughts of harming yourself, at any intensity. This is immediate and not something to monitor.
A persistent low mood lasting more than a couple of weeks, particularly if it is unlike you.
A clear change in mood beginning shortly after starting or after a dose increase.
Any change while you are also taking medication for a mental health condition, since that combination deserves review rather than assumption.
Anything that worries the people around you, even if it does not yet worry you.

A prescriber can only act on what they hear about, and mood is the thing people are least likely to raise in a fifteen-minute appointment about weight.

What to record

This is worth keeping deliberately light. An elaborate mood-tracking system abandoned in three weeks is worse than a single line a week that survives six months.

A rough sense of how the week went, noted during it.
Dose changes with dates, so the two can be laid alongside each other.
Sleep, if anything about it has changed. It moves mood more than most things and it changes on these medications.
Anything you want to raise at the next appointment, written when you think of it rather than remembered on the day.

Penwise keeps notes and symptoms against dates and doses, and stores them on your device rather than on a server, which for this particular category of note is the relevant fact. The privacy page covers what that means in practice.

Notes that stay on your phone

Mood, symptoms and doses on one timeline, stored on your device rather than on a server. Free core tracker, no account needed.

Download on the App Store Get it on Google Play

Common questions

Do GLP-1 medications cause depression?

The European Medicines Agency reviewed the signal and concluded in April 2024 that the available evidence does not support a causal association between GLP-1 receptor agonists and suicidal and self-injurious thoughts and actions, and that no product information update was warranted. That is a population-level finding and not a reason to ignore a change you notice in yourself.

What did the EMA review of suicidal thoughts find?

The review began in July 2023 after case reports involving liraglutide and semaglutide. Drawing on non-clinical studies, trial data, post-marketing surveillance and a study of electronic health records, the safety committee concluded in April 2024 that the evidence does not support a causal association.

Why do I feel flat on Ozempic or Mounjaro?

Several explanations overlap and are hard to separate: a broader dulling reported alongside the quieting of food noise, the loss of eating as a coping mechanism, weeks of feeling physically unwell after a dose increase, and the social changes that come with substantial weight loss. It is worth raising with a prescriber rather than sitting with.

Should I stop taking it if my mood has changed?

Talk to your prescriber rather than stopping on your own. If you are having thoughts of harming yourself, contact your doctor, an emergency service or a crisis line now, without waiting to establish whether the medication is involved.

Can these medications interact with antidepressants?

Any change in mood while you are also taking medication for a mental health condition deserves a proper review with the prescriber who manages it, rather than an assumption in either direction. Bring the dates of both, since timing is the most informative thing you can offer.

How do I tell whether the medication caused it?

Largely by timing, which is why dates matter more than anything else here. A change beginning within days of a dose increase and a change that drifted in over two months are different findings, and memory reconstructs that distinction badly. A brief note made during the week is worth more than a careful recollection months later.

Sources

Every factual claim on this page traces to the product information a regulator publishes, or to a published trial. Links open on the site of whoever issued the document.

PRAC: available evidence does not support a link between GLP-1 receptor agonists and suicidal and self-injurious thoughts and actions European Medicines Agency, April 2024
Wegovy: EPAR product information European Medicines Agency
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021

Penwise is a tracking and education tool, not a medical device. Nothing on this page is medical advice, a diagnosis or a recommendation to start, stop or change a dose. Dosing decisions belong to you and your clinician. Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are trademarks of Novo Nordisk; Mounjaro, Zepbound and Trulicity are trademarks of Eli Lilly. Penwise is not affiliated with, endorsed by or connected to either company.

GLP-1 medications and mood: what the reviews found